You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永泰生物-B(06978.HK)拟在北京兴建新生物药物研发及产业化基地
格隆汇 03-29 22:24

格隆汇 3 月 29日丨永泰生物-B(06978.HK)发布公告,2021年3月26日,公司透过其间接全资附属公司北京永泰与中建三局订立建造协议,内容有关在北京兴建研发及产业化基地,合约金额为人民币6.65亿元。

公告表示,2020年,集团成功投得一幅位于北京市北京经济技术开发区路南区的地块,用作建造一个具规模的生产中心,作为集团增长计划的一部分。此外,由于集团核心在研产品EAL®是基于活体细胞生产,而活体细胞需要在有限时间内送达,集团长久以来的计划为在中国主要城市(包括北京)距离中国人口稠密的地区不远的地方建立生产中心。

为配合及筹备集团核心在研产品及其他在研产品的商业化,集团有意在位于北京的该土地上兴建研发及产业化基地。尤其是,建造工程包括多幢用作细胞疗法及其他生产车间及质检的建筑物,可让集团因应集团核心在研产品及其他在研产品的商业化进行必要的研发工作、测试及质量保证程序。

因此,北京永泰订立建造协议与上述意向及集团的业务策略一致,故此,董事会认为建造协议乃北京永泰与中建三局经公平磋商后,按一般商业条款订立,而建造工程属公平及合理,并符合公司及股东整体的利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account